Abstract
The presence of axillary nodal metastases has a significant impact on locoregional and systemic treatment decisions. Historically, all node-positive patients underwent complete axillary lymph node dissection; however, this paradigm has changed over the last 10 years. The use of sentinel lymph node dissection has expanded from its initial role as a surgical staging procedure in clinically node-negative patients. Clinically node-negative patients with small volume disease found on sentinel lymph node dissection now commonly avoid more extensive axillary surgery. There is interest in expanding this role to node-positive patients who receive neoadjuvant chemotherapy as a way to restage the axilla in hopes of sparing women who convert to node-negative status from the morbidity of complete nodal clearance. While sentinel lymph node dissection alone may not accomplish this goal, there are novel techniques, such as targeted axillary dissection, that may now allow for reliable nodal staging after chemotherapy.
Original language | English (US) |
---|---|
Article number | 149 |
Journal | BMC medicine |
Volume | 13 |
Issue number | 1 |
DOIs | |
State | Published - Jun 25 2015 |
Keywords
- Axillary lymphadenectomy
- Breast cancer
- Neoadjuvant chemotherapy
- Nodal metastasis
- Sentinel lymph node
- Targeted axillary dissection
ASJC Scopus subject areas
- General Medicine